Kaliumchloride Fresenius Kabi (Potassium Chloride)

After intravenous administration, potassium chloride dissociates into potassium ions that enter the extracellular fluid. The increased extracellular potassium shifts the electrochemical gradient across cell membranes, facilitating repolarization of cardiac and skeletal muscle cells, correcting low potassium levels, and maintaining normal cellular excitability.

The dose of Kaliumchloride Fresenius Kabi is individualized by the prescribing clinician based on the patient’s current serum potassium concentration, renal function, cardiac status, and the rate of potassium loss. The prescriber calculates the required amount to safely raise potassium to the target range.

Safety data for potassium chloride in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional after evaluating the clinical situation.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Kaliumchloride Fresenius Kabi is an injectable formulation, allowing rapid correction of potassium deficits in acute settings, whereas oral potassium salts are slower and used for chronic management. The IV product offers precise dosing and immediate bioavailability, which is essential for severe hypokalemia or when oral intake is not feasible.

The solution must be stored at 2‑8 °C, kept refrigerated, protected from light, and should never be frozen or shaken. Before use, inspect the container for particulate matter or discoloration, and follow aseptic techniques to prevent contamination during preparation and administration.

Kaliumchloride Fresenius Kabi is administered intravenously by a qualified healthcare professional. The infusion rate is carefully controlled, typically not exceeding 10‑20 mmol per hour, to minimize the risk of local irritation and rapid shifts in serum potassium. Monitoring of cardiac rhythm and serum potassium is recommended during and after infusion.

The most serious risks include severe hyperkalemia, which can cause life‑threatening cardiac arrhythmias or cardiac arrest, as well as anaphylactic reactions and thrombophlebitis at the infusion site. Prompt recognition and immediate medical intervention are essential if these events occur.

Patients with known hypersensitivity to potassium chloride or any component of the formulation should avoid the product. It is also contraindicated in individuals with severe renal failure, uncontrolled hyperkalemia, or conditions where rapid potassium elevation could precipitate dangerous cardiac events.